Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garcia-Escobar, I; Beato-Zambrano, C; Langa, JM; Vazquez, EB; Portero, BO; Gutierrez-Abad, D; Martin, AJM.

Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(9): 1097-1108 Nº de citas: 13 [doi:10.1007/s12094-018-1835-2]

Aranda, E; Garcia-Alfonso, P; Benavides, M; Ruiz, AS; Guillen-Ponce, C; Safont, MJ; Alcaide, J; Gomez, A; Lopez, R; Manzano, JL; Urena, MM; Sastre, J; Rivera, F; Gravalos, C; Garcia, T; Martin-Valades, JI; Falco, E; Navalon, M; Flores, EG; Tapiador, AMG; Munoz, AML; Barrajon, E; Reboredo, M; Teijido, PG; Viudez, A; Cardenas, N; Diaz-Rubio, E.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

EUROPEAN JOURNAL OF CANCER. 2018; 101: 263-272 Nº de citas: 66 [doi:10.1016/j.ejca.2018.06.024]

Litton, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Quek, RGW; Markova, D; Tudor, IC; Hannah, AL; Eiermann, W; Blum, JL.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

NEW ENGLAND JOURNAL OF MEDICINE. 2018; 379(8): 753-763 Nº de citas: 1604 [doi:10.1056/NEJMoa1802905]

Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Vidam, G; Wang, YB; Lorenc, KR; Miller, M; Taran, T; Jerusalem, G.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(24): 2465-2472 Nº de citas: 833 [doi:10.1200/JCO.2018.78.9909]

Carmona-Bayonas, A; Jimenez-Fonseca, P; Echavarria, I; Canovas, MS; Aguado, G; Gallego, J; Custodio, A; Hernandez, R; Viudez, A; Cano, JM; de Castro, EM; Macias, I; Carnicero, AM; Garrido, M; Mangas, M; Mancenido, FA; Visa, L; Azkarate, A; Ramchandani, A; Montes, AF; Longo, F; Sanchez, A; Pimentel, P; Limon, ML; Arias, D; Lavin, DC; Bayona, RS; Cerda, P; Alfonso, PG; AGAMENON Study Grp.

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

EJSO. 2018; 44(8): 1191-1198 Nº de citas: 48 [doi:10.1016/j.ejso.2018.03.019]

Girones, R; Morilla, I; Guillen-Ponce, C; Torregrosa, MD; Paredero, I; Bustamante, E; del Barco, S; Soler, G; Losada, B; Visa, L; Llabres, E; Fox, B; Firvida, JL; Blanco, R; Antonio, M; Aparisi, F; Pi-Figueras, M; Gonzalez-Flores, E; Molina-Garrido, MJ; Saldana, J; Spanish Soc Med Oncology SEOM.

Geriatric oncology in Spain: survey results and analysis of the current situation

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(8): 1087-1092 Nº de citas: 11 [doi:10.1007/s12094-017-1813-0]

Lobo, M; Lopez-Tarruella, S; Luque, S; Lizarraga, S; Flores-Sanchez, C; Bueno, O; Solera, J; Jerez, Y; del Val, RG; Palomero, MI; Cebollero, M; Echavarria, I; Torres, G; Martin, M; Marquez-Rodas, I.

Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit

Journal of Genetic Counseling. 2018; 27(4): 854-862 Nº de citas: 7 [doi:10.1007/s10897-017-0187-3]

Ascierto, PA; Bastholt, L; Ferrucci, PF; Hansson, J; Rodas, IM; Payne, M; Robert, C; Thomas, L; Utikal, JS; Wolter, P; Kudlac, A; Tuson, H; McKendrick, J.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

MELANOMA RESEARCH. 2018; 28(4): 333-340 Nº de citas: 14 [doi:10.1097/CMR.0000000000000455]

Cazet, AS; Hui, MN; Elsworth, BL; Wu, SZ; Roden, D; Chan, CL; Skhinas, JN; Collot, R; Yang, J; Harvey, K; Johan, MZ; Cooper, C; Nair, R; Herrmann, D; McFarland, A; Deng, NT; Ruiz-Borrego, M; Rojo, F; Trigo, JM; Bezares, S; Caballero, R; Lim, E; Timpson, P; O'Toole, S; Watkins, DN; Cox, TR; Samuel, MS; Martin, M; Swarbrick, A.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

Nature Communications. 2018; 9: 2897-2897 Nº de citas: 344 [doi:10.1038/s41467-018-05220-6]

Martinez-Laperche, C; Buces, E; Aguilera-Morillo, MC; Picornell, A; Gonzalez-Rivera, M; Lillo, R; Santos, N; Martin-Antonio, B; Guillem, V; Nieto, JB; Gonzalez, M; de la Camara, R; Brunet, S; Jimenez-Velasco, A; Espigado, I; Vallejo, C; Sampol, A; Bellon, JM; Serrano, D; Kwon, M; Gayoso, J; Balsalobre, P; Urbano-Izpizua, A; Solano, C; Gallardo, D; Diez-Martin, JL; Romo, J; Buno, I.

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

Blood Advances. 2018; 2(14): 1719-1737 Nº de citas: 20 [doi:10.1182/bloodadvances.2017011502]

Garrido P; Aldaz A; Calleja MA; de Alava E; Lamas MJ; Martin M; Matias-Guiu X; Palacios J; Vera R.

Propuesta para la creacion de una Estrategia Nacional sobre Medicina de Precision en Cancer: posicionamiento de la SEOM, SEAP y SEFH.

Revista Espanola de Patologia. 2018; 51(3): 154-159 Nº de citas: 1 [doi:10.1016/j.patol.2017.10.003]

Colomer, R; Aranda-Lopez, I; Albanell, J; Garcia-Caballero, T; Ciruelos, E; Lopez-Garcia, MA; Cortes, J; Rojo, F; Martin, M; Palacios-Calvo, J.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(7): 815-826 Nº de citas: 56 [doi:10.1007/s12094-017-1800-5]

Pernas, S; Martin, M; Kaufman, PA; Gil-Martin, M; Pardo, PG; Lopez-Tarruella, S; Manso, L; Ciruelos, E; Perez-Fidalgo, JA; Hernando, C; Ademuyiwa, FO; Weilbaecher, K; Mayer, I; Pluard, TJ; Garcia, MM; Vahdat, L; Perez-Garcia, J; Wach, A; Barker, D; Fung, S; Romagnoli, B; Cortes, J.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

LANCET ONCOLOGY. 2018; 19(6): 812-824 Nº de citas: 125 [doi:10.1016/S1470-2045(18)30147-5]

Gravalos, C; Carrato, A; Tobena, M; Rodriguez-Garrote, M; Soler, G; Vieitez, JM; Robles, L; Valladares-Ayerbes, M; Polo, E; Limon, ML; Safont, MJ; de Castro, EM; Garcia-Alfonso, P; Aranda, E.

A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

CLINICAL COLORECTAL CANCER. 2018; 17(2): 323-329 Nº de citas: 17 [doi:10.1016/j.clcc.2018.02.004]

Santonja A; Sanchez-Munoz A; Lluch A; Chica-Parrado MR; Albanell J; Chacon JI; Antolin S; Jerez JM; de la Haba J; de Luque V; Fernandez-De Sousa CE; Vicioso L; Plata Y; Ramirez-Tortosa CL; Alvarez M; Llacer C; Zarcos-Pedrinaci I; Carrasco E; Caballero R; Martin M; Alba E.

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

Oncotarget. 2018; 9(41): 26406-26416 Nº de citas: 154 [doi:10.18632/oncotarget.25413]

Hill, AG; Findlay, MP; Burge, ME; Jackson, C; Alfonso, PG; Samuel, L; Ganju, V; Karthaus, M; Amatu, A; Jeffery, M; Di Bartolomeo, M; Bridgewater, J; Coveler, AL; Hidalgo, M; Kapp, AV; Sufan, RI; McCall, BB; Hanley, WD; Penuel, EM; Pirzkall, A; Tabernero, J.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

CLINICAL CANCER RESEARCH. 2018; 24(10): 2276-2284 Nº de citas: 53 [doi:10.1158/1078-0432.CCR-17-0646]

Alfonso, PG; Podesta, MC; Martin, AM; Codeisido, MB; Calvo, A; Peligros, I; Corcuera, A; Blanco, ABR; Custodio-Cabello, S; Trabada, DL; Martin, M; De Ramon, E.

Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases

ANTICANCER RESEARCH. 2018; 38(5): 3069-3077 Nº de citas: 4 [doi:10.21873/anticanres.12564]

Martin, M; Campone, M; Bondarenko, I; Sakaeva, D; Krishnamurthy, S; Roman, L; Lebedeva, L; Vedovato, JC; Aapro, M.

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

ANNALS OF ONCOLOGY. 2018; 29(5): 1195-1202 Nº de citas: 12 [doi:10.1093/annonc/mdy063]